DDInter856 DDInter621
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Edoxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Edoxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenyl salicylate
Edoxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Edoxaban {u} may lead to a major life threatening interaction when taken with {v} Reteplase
Edoxaban {u} may lead to a major life threatening interaction when taken with {v} Velpatasvir
Edoxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Edoxaban may lead to a major life threatening interaction when taken with Reteplase
Edoxaban may lead to a major life threatening interaction when taken with Velpatasvir